CARsgen and Moderna Collaborate to Evaluate CT041 + mRNA Cancer Vaccine
Shots:
- The companies collaborated to evaluate CARsgen's Claudin18.2 CAR T-cell product candidate (CT041) + Moderna’s Claudin18.2 mRNA cancer vaccine in the preclinical studies and a P-I clinical trial
- The collaboration focuses to explore the potential synergy of CAR-T + mRNA cancer vaccine that encodes for the Claudin18.2 protein. CT041 is being investigated for the treatment of gastric, pancreatic, and other specified digestive system cancers and it is currently in multiple ongoing clinical studies in China and North America
- CT041 received the RMAT designation & ODD from the US FDA for advanced GC/GEJ; PRIME eligibility & Orphan Medicinal Product designation from the EMA for advanced gastric cancer
Ref: CARsgen | Image: CARsgen
Related News:- CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
